Evommune Starts Making Case to Challenge Dominance of Sanofi’s Dupixent in Atopic Dermatitis

Evommune’s EVO301 met the goals of a placebo-controlled Phase 2a study in atopic dermatitis. The biologic drug neutralizes a signaling protein involved in multiple inflammatory pathways, which could differentiate it from the blockbuster Sanofi and Regeneron Pharmaceuticals immunology drug Dupixent. The post Evommune Starts Making Case to Challenge Dominance of Sanofi’s Dupixent in Atopic Dermatitis…

Read More

Nearly Four Million Medicare Beneficiaries Could Be Eligible for the Temporary Medicare GLP-1 Bridge Program Covering These Drugs for Weight Loss

This news release highlights that a KFF analysis finds that 3.8 million Medicare beneficiaries met the criteria to be eligible for the new Medicare GLP-1 Bridge, based on claims data from 2023. The temporary program will provide coverage of three GLP-1 drugs used for weight reduction and weight management to eligible Medicare beneficiaries.

Read More

Indiana – It is the best of times, and the worst of times

By MIKE MAGEE “Hoosiers receive heroes’ welcome in return to Bloomington” screamed last week’s ESPN headline, as IU claimed top spot in college football nationwide. It’s been awhile since sports elevated that state’s mood. In his classic review of the famous movie, “The Hoosiers,” Roger Ebert writes, “This is a movie about a tiny Indiana…

Read More

‘Serial Killing’ Cell Therapy From Autolus Lands FDA Approval in Blood Cancer

Autolus Therapeutics’ Aucatzyl is now FDA approved for treating advanced cases of B-cell precursor acute lymphoblastic leukemia. While it goes after the same target as Gilead Sciences’ Tecartus, Autolus engineered its CAR T-therapy with properties that could improve safety, efficacy, and durability. The post ‘Serial Killing’ Cell Therapy From Autolus Lands FDA Approval in Blood…

Read More